Home › Graft-Versus-Host Disease › California
Graft-Versus-Host Disease clinical trials in California
9 studies for Graft-Versus-Host Disease are looking for participants at sites in California.
Cities in California
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- UCLA Department of Medicine, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jul 1, 2026 · NCT06996119Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jun 29, 2026 · NCT06815003A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 16, 2026 · NCT04710576A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- Stanford Cancer Center, Palo Alto
- University of California San Francisco, San Francisco
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06615050A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
- University of California, San Francisco, San Francisco
Recruiting
Up to age 30 · All sexes · Updated Apr 13, 2026 · NCT04337515A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- City of Hope National Medical Center, Duarte
- Ronald Regan UCLA Medical Center, Los Angeles
- University of California Irvine Health, Orange
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
- Stanford Hospital, Stanford
RecruitingObservational study
36 Months · All sexes · Updated Oct 20, 2025 · NCT05866302Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.